GHNasdaq

Guardant Health Inc.

Healthcare·Oncology·Palo Alto, CA, United States
OncologyDermatologyNephrology

Guardant Health Inc. (GH): 1 pipeline candidate · ~57 mo cash runway · 7 clinical trials. Updated within the last hour.

5.8/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway10.0

57.4 months

Financial Health10.0

D/E -11.58 · 0% dilution

Pipeline MaturityN/A

N/A

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider Signal0.0

0 buys · 43 sells (180d)

A transparent, data-derived signal for Guardant Health Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$17.0B

Cash

$1.1B

Quarterly Burn

$65.6M

Runway

57.4 mo

Revenue

$301.7M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Mar 2031
Today~63 mo out
Catalyst within runway

Pipeline (1 candidate)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

484

Total value held

$11.53B

HolderSharesValue
blackrock, inc.11,553,759$1.07B
vanguard capital management llc11,248,360$1.04B
vanguard portfolio management llc5,837,992$539.3M
goldman sachs group inc4,435,839$409.7M
two sigma investments, lp4,229,531$390.7M
fmr llc4,116,081$380.2M
geode capital management, llc3,508,883$324.2M
capital international investors3,481,318$321.6M
franklin resources inc3,448,193$318.5M
deep track capital, lp3,338,241$308.4M

Showing top 10 of 484 institutional holders of Guardant Health Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

7 clinical trials·1 FDA decision·CEO: Dr. Helmy Eltoukhy Ph.D.

Frequently asked questions

How many drug candidates are in Guardant Health Inc.'s pipeline?

Guardant Health Inc. (GH) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is Guardant Health Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Guardant Health Inc. has approximately 57.4 months of cash runway.

What is Guardant Health Inc.'s market capitalization?

Guardant Health Inc.'s market capitalization is approximately $17.0B.

Who is the CEO of Guardant Health Inc.?

Dr. Helmy Eltoukhy Ph.D. is the chief executive officer of Guardant Health Inc. (GH).

Get the full picture on Guardant Health Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.